|
Loizou, G D; Urban, G; Dekant, W et al. (1994) Gas-uptake pharmacokinetics of 2,2-dichloro-1,1,1-trifluoroethane (HCFC-123). Drug Metab Dispos 22:511-7
|
|
Yin, H; Jones, J P; Anders, M W (1993) Slow-binding inhibition of carboxylesterase and other serine hydrolases by chlorodifluoroacetaldehyde. Chem Res Toxicol 6:630-4
|
|
Loizou, G D; Anders, M W (1993) Gas-uptake pharmacokinetics and biotransformation of 1,1-dichloro-1-fluoroethane (HCFC-141b). Drug Metab Dispos 21:634-9
|
|
Harris, J W; Jones, J P; Martin, J L et al. (1992) Pentahaloethane-based chlorofluorocarbon substitutes and halothane: correlation of in vivo hepatic protein trifluoroacetylation and urinary trifluoroacetic acid excretion with calculated enthalpies of activation. Chem Res Toxicol 5:720-5
|
|
Harris, J W; Anders, M W (1991) In vivo metabolism of the hydrochlorofluorocarbon 1,1-dichloro-1-fluoroethane (HCFC-141b). Biochem Pharmacol 41:R13-6
|
|
Harris, J W; Anders, M W (1991) Metabolism of the hydrochlorofluorocarbon 1,2-dichloro-1,1-difluoroethane. Chem Res Toxicol 4:180-6
|
|
Harris, J W; Pohl, L R; Martin, J L et al. (1991) Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoroethane. Proc Natl Acad Sci U S A 88:1407-10
|
|
Anders, M W (1991) Metabolism and toxicity of hydrochlorofluorocarbons: current knowledge and needs for the future. Environ Health Perspect 96:185-91
|
